AR109774A1 - Compuestos heterocíclicos y su uso en la prevención o el tratamiento de infecciones bacterianas - Google Patents
Compuestos heterocíclicos y su uso en la prevención o el tratamiento de infecciones bacterianasInfo
- Publication number
- AR109774A1 AR109774A1 ARP170102732A ARP170102732A AR109774A1 AR 109774 A1 AR109774 A1 AR 109774A1 AR P170102732 A ARP170102732 A AR P170102732A AR P170102732 A ARP170102732 A AR P170102732A AR 109774 A1 AR109774 A1 AR 109774A1
- Authority
- AR
- Argentina
- Prior art keywords
- nq1q2
- heterocycle
- nq1c
- nhq3
- different
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), donde R¹ representa un heterociclo de 5 miembros, opcionalmente sustituido con uno o varios T¹, saturado, parcialmente insaturado o aromático que comprende al menos un átomo de nitrógeno, estando ligado el heterociclo con la estructura por el átomo de nitrógeno, al menos uno de los átomos de nitrógeno puede estar cuaternizado; R² representa -SO₃H, -CFHCOOH o -CF₂COOH; T¹, igual o diferente, representa, de modo independiente, un átomo de flúor; =O; -C(O)Q¹; -(CH₂)ₘ-S(O)₂-NQ¹Q²; -(CH₂)ₘ-C(=NOQ¹)Q³; -(X)-(CH₂)ₚ-S(O)₂NQ¹Q²; -C(O)-(CH₂)ₙ-S(O)₂NQ¹Q²; -(CH₂)ₘ-O-(CH₂)ₚ-O-(CH₂)ₚ-NQ¹Q²; -(CH₂)ₘOQ¹; -(CH₂)ₘ-CN; -(CH₂)ₘ-OC(O)Q¹; -(CH₂)ₘ-C(O)OQ¹; -(CH₂)ₘ-OC(O)OQ¹; -(CH₂)ₘ-OC(O)NQ¹Q²; -(CH₂)ₘ-C(O)NQ¹Q²; -(CH₂)ₘ-C(O)ONQ¹Q²; -(CH₂)ₘ-C(O)NQ¹OQ²; -(CH₂)ₘ-C(O)NQ¹-NQ¹Q²; -(CH₂)ₘ-NQ¹C(O)Q²; -(CH₂)ₘ-NQ¹S(O)₂NQ¹Q²; -(CH₂)ₘ-NQ¹S(O)₂Q²; -(CH₂)ₘ-NQ¹C(O)OQ²; -(CH₂)ₘ-NQ¹C(O)NQ¹Q²; -(CH₂)ₘ-NQ¹Q²; -(CH₂)ₘ-NH-C(NHQ³)=NQ⁴; -(CH₂)ₘ-NH-CH=NQ³; -(CH₂)ₘ-C(NHQ³)=NQ⁴; -(X)-(CH₂)ₚOQ¹; -(X)-(CH₂)ₙ-CN; -(X)-(CH₂)ₚ-OC(O)Q¹; -(X)-(CH₂)ₙ-C(O)OQ¹; -(X)-(CH₂)ₚ-OC(O)OQ¹; -(X)-(CH₂)ₚ-OC(O)NQ¹Q²; -(X)-(CH₂)ₙ-C(O)NQ¹Q²; -(X)-(CH₂)ₙ-C(O)ONQ¹Q²; -(X)-(CH₂)ₙ-C(O)NQ¹OQ²; -(X)-(CH₂)ₙ-C(O)NQ¹-NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹C(O)Q²; -(X)-(CH₂)ₚ-NQ¹S(O)₂NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹S(O)₂Q²; -(X)-(CH₂)ₚ-NQ¹C(O)OQ²; -(X)-(CH₂)ₚ-NQ¹C(O)NQ¹Q²; -(X)-(CH₂)ₚ-NQ¹Q²; -(X)-(CH₂)ₚ-NH-C(NHQ³)=NQ⁴; -(X)-(CH₂)ₚ-NH-CH=NQ³; -(X)-(CH₂)ₙ-C(NHQ³)=NQ⁴; -C(O)-(CH₂)ₙOQ¹; -C(O)-(CH₂)ₙ-CN; -C(O)-(CH₂)ₙ-OC(O)Q¹; -C(O)-(CH₂)ₙ-C(O)OQ¹; -C(O)-(CH₂)ₙ-OC(O)OQ¹; -C(O)-(CH₂)ₙ-OC(O)NQ¹Q²; -C(O)-(CH₂)ₙ-C(O)NQ¹Q²; -C(O)-(CH₂)ₙ-C(O)ONQ¹Q²; -C(O)-(CH₂)ₙ-C(O)NQ¹OQ²; -C(O)-(CH₂)ₙ-C(O)NQ¹-NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹C(O)Q²; -C(O)-(CH₂)ₙ-NQ¹S(O)₂NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹S(O)₂Q²; -C(O)-(CH₂)ₙ-NQ¹C(O)OQ²; -C(O)-(CH₂)ₙ-NQ¹C(O)NQ¹Q²; -C(O)-(CH₂)ₙ-NQ¹Q²; -C(O)-(CH₂)ₙ-NH-C(NHQ³)=NQ⁴; -C(O)-(CH₂)ₙ-NH-CH=NQ³; -C(O)-(CH₂)ₙ-C(NHQ³)=NQ⁴ o T¹, igual o diferente, representa, de modo independiente, un heterociclo no sustituido o sustituido con uno o varios T², -(CH₂)ₘ-(heterociclo de 4, 5 ó 6 miembros saturado, parcial o totalmente insaturado o aromático); -(X)-(CH₂)ₘ-(heterociclo de 4, 5 ó 6 miembros saturado, parcial o totalmente insaturado o aromático); alquilo C₁₋₃; fluoroalquilo C₁₋₃; -(X)-alquilo C₁₋₃; -(X)-fluoroalquilo C₁₋₃; -(CH₂)ₘ-cicloalquilo C₃₋₆; -(X)-(CH₂)ₘ-cicloalquilo C₃₋₆; -(CH₂)ₘ-ciclofluoroalquilo C₃₋₆; -(X)-(CH₂)ₘ-ciclofluoroalquilo C₃₋₆; -C(O)-(CH₂)ₘ-(heterociclo de 4, 5 ó 6 miembros saturado, parcial o totalmente insaturado o aromático); -C(O)-alquilo C₁₋₃; -C(O)-fluoroalquilo C₁₋₃; -C(O)O-fluoroalquilo C₁₋₃; -C(O)-(CH₂)ₘ-cicloalquilo C₃₋₆; -C(O)-(CH₂)ₘ-cicloalquilo C₃₋₆; -C(O)-(CH₂)ₘ-ciclofluoroalquilo C₃₋₆; -C(O)-(CH₂)ₘ-ciclofluoroalquilo C₃₋₆; T², igual o diferente, representa, de modo independiente, -OH; -NH₂; -CONH₂; Q¹ y Q², iguales o diferentes, representan, de modo independiente, un átomo de hidrógeno; -(CH₂)ʳ-NHQ³; -(CH₂)ʳ-NH-C(NHQ³)=NQ⁴; -(CH₂)ʳ-NH-CH=NQ³; (CH₂)ₙ-C(NHQ³)=NQ⁴; -(CH₂)ʳ-OQ³; -(CH₂)ₙ-CONHQ³; o un alquilo C₁₋₃ no sustituido o sustituido con uno o varios T²; fluoroalquilo C₁₋₃; heterociclo saturado, parcial o totalmente insaturado o aromático-(CH₂)ₘ-(de 4, 5 ó 6 miembros que comprende al menos un átomo de nitrógeno); o Q¹, Q² y el átomo de nitrógeno al que están unidos, forman juntos un heterociclo no sustituido o sustituido con uno o varios T², saturado o parcialmente insaturado de 4, 5 ó 6 miembros que comprende 1, 2 ó 3 heteroátomos; Q³ y Q⁴, iguales o diferentes, representan, de modo independiente, un átomo de hidrógeno o alquilo C₁₋₃; m, igual o diferente, representa, de modo independiente, 0, 1, 2 ó 3; n, igual o diferente, representa, de modo independiente, 1, 2 ó 3; p, igual o diferente, representa, de modo independiente, 2 ó 3; r es 1, 2 ó 3 cuando el (CH₂)ʳ está directamente ligado con un átomo de carbono o 2 ó 3 de otro modo, con preferencia, r es 2 ó 3; X, igual o diferente, representa, de modo independiente, O; S; S(O); S(O)₂ o N(Q³); donde cualquier átomo de carbono presente dentro de un grupo seleccionado de alquilo, cicloalquilo, fluoroalquilo, ciclofluoroalquilo y heterociclo se puede oxidar para formar un grupo C=O; cualquier átomo de azufre presente dentro de un heterociclo se puede oxidar para formar un grupo S=O o un grupo S(O)₂; cualquier átomo de nitrógeno presente dentro de un heterociclo o presente dentro de un grupo donde está trisustituido, formando así un grupo amino terciario, se puede cuaternizar con un grupo metilo; y uno de sus racematos, enantiómeros, diastereoisómeros, isómeros geométricos o una de sus sales farmacéuticamente aceptables, a excepción de los compuestos de fórmula (2), (3) y (4).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306261.5A EP3301094A1 (en) | 2016-09-30 | 2016-09-30 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109774A1 true AR109774A1 (es) | 2019-01-23 |
Family
ID=57130331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102732A AR109774A1 (es) | 2016-09-30 | 2017-09-29 | Compuestos heterocíclicos y su uso en la prevención o el tratamiento de infecciones bacterianas |
Country Status (24)
Country | Link |
---|---|
US (1) | US10722520B2 (es) |
EP (3) | EP3301094A1 (es) |
JP (2) | JP7089508B2 (es) |
KR (1) | KR20190065326A (es) |
CN (2) | CN109906226B (es) |
AR (1) | AR109774A1 (es) |
AU (1) | AU2017335222C1 (es) |
BR (1) | BR112019006371A2 (es) |
CA (1) | CA3038221A1 (es) |
CL (1) | CL2019000857A1 (es) |
DK (1) | DK3519411T3 (es) |
ES (1) | ES2927528T3 (es) |
HR (1) | HRP20220831T1 (es) |
HU (1) | HUE059938T2 (es) |
IL (1) | IL265676B (es) |
LT (1) | LT3519411T (es) |
MX (1) | MX2019003545A (es) |
PL (1) | PL3519411T3 (es) |
PT (1) | PT3519411T (es) |
RS (1) | RS63473B1 (es) |
SI (1) | SI3519411T1 (es) |
TW (1) | TWI801353B (es) |
WO (1) | WO2018060481A1 (es) |
ZA (1) | ZA201901963B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
CA3120371A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
JP2024503893A (ja) * | 2021-01-21 | 2024-01-29 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン-アニリン化合物を調製するための方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
AU2005273619B2 (en) * | 2004-08-18 | 2009-05-28 | Pfizer Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
FR2930553B1 (fr) * | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
FR2937034B1 (fr) * | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
US8138189B2 (en) | 2009-03-26 | 2012-03-20 | Hoffman-La Roche Inc. | Substituted benzene compounds as modulators of the glucocorticoid receptor |
TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
US8791091B2 (en) * | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
US9487474B2 (en) | 2012-06-04 | 2016-11-08 | Elkimia, Inc. | Imino compounds as protecting agents against ultraviolet radiations |
WO2014102759A2 (en) | 2012-12-31 | 2014-07-03 | Ranbaxy Laboratories Limited | Process for the preparation of dasatinib and its intermediates |
WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
US20140315876A1 (en) * | 2013-03-15 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CN107980000A (zh) * | 2014-04-18 | 2018-05-01 | 沃克哈特有限公司 | 包含抗菌剂的药物组合物 |
RS58429B1 (sr) * | 2014-11-17 | 2019-04-30 | Entasis Therapeutics Ltd | Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija |
CN105704828A (zh) * | 2014-11-25 | 2016-06-22 | 中兴通讯股份有限公司 | 一种资源调度的方法和装置 |
JP6767392B2 (ja) * | 2015-05-07 | 2020-10-14 | ミュタビリスMutabilis | 複素環式化合物及び細菌感染の治療又は予防におけるその使用 |
EP3091018A1 (en) * | 2015-05-07 | 2016-11-09 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
-
2016
- 2016-09-30 EP EP16306261.5A patent/EP3301094A1/en not_active Withdrawn
-
2017
- 2017-09-29 DK DK17783790.3T patent/DK3519411T3/da active
- 2017-09-29 CN CN201780066906.5A patent/CN109906226B/zh active Active
- 2017-09-29 CN CN202111181134.4A patent/CN113929680A/zh active Pending
- 2017-09-29 MX MX2019003545A patent/MX2019003545A/es unknown
- 2017-09-29 EP EP17783790.3A patent/EP3519411B1/en active Active
- 2017-09-29 HR HRP20220831TT patent/HRP20220831T1/hr unknown
- 2017-09-29 TW TW106133607A patent/TWI801353B/zh active
- 2017-09-29 JP JP2019516955A patent/JP7089508B2/ja active Active
- 2017-09-29 CA CA3038221A patent/CA3038221A1/en active Pending
- 2017-09-29 AR ARP170102732A patent/AR109774A1/es unknown
- 2017-09-29 PL PL17783790.3T patent/PL3519411T3/pl unknown
- 2017-09-29 RS RS20220757A patent/RS63473B1/sr unknown
- 2017-09-29 WO PCT/EP2017/074873 patent/WO2018060481A1/en unknown
- 2017-09-29 US US16/338,355 patent/US10722520B2/en active Active
- 2017-09-29 PT PT177837903T patent/PT3519411T/pt unknown
- 2017-09-29 LT LTEPPCT/EP2017/074873T patent/LT3519411T/lt unknown
- 2017-09-29 SI SI201731177T patent/SI3519411T1/sl unknown
- 2017-09-29 ES ES17783790T patent/ES2927528T3/es active Active
- 2017-09-29 HU HUE17783790A patent/HUE059938T2/hu unknown
- 2017-09-29 AU AU2017335222A patent/AU2017335222C1/en active Active
- 2017-09-29 KR KR1020197011894A patent/KR20190065326A/ko active IP Right Grant
- 2017-09-29 BR BR112019006371A patent/BR112019006371A2/pt unknown
- 2017-09-29 EP EP22180040.2A patent/EP4086255A1/en not_active Withdrawn
-
2019
- 2019-03-27 IL IL265676A patent/IL265676B/en unknown
- 2019-03-29 ZA ZA2019/01963A patent/ZA201901963B/en unknown
- 2019-03-29 CL CL2019000857A patent/CL2019000857A1/es unknown
-
2022
- 2022-04-14 JP JP2022067010A patent/JP2022097520A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
AR055144A1 (es) | Inhibidor de secrecion acida | |
AR113688A1 (es) | Proceso para la preparación de compuestos de piridiminio ópticamente activo | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
AR109774A1 (es) | Compuestos heterocíclicos y su uso en la prevención o el tratamiento de infecciones bacterianas | |
AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
ES2678086T3 (es) | Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos | |
AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
AR099469A1 (es) | Fungicidas derivados de oxoborazoles | |
AR108778A1 (es) | Compuestos antibacterianos | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
AR098101A1 (es) | Composiciones plaguicidas y métodos relacionados | |
AR113958A1 (es) | Macrociclos a como inhibidores de pde1 |